Conference Coverage
Conference Coverage
Are single agents better than chemo for relapsed/refractory PTCL?
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Conference Coverage
mRECIST response to kinase inhibitors predicts survival in HCC
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...
Conference Coverage
Pembrolizumab bests chemo in PD-L1-positive esophageal cancer
SAN FRANCISCO – In KEYNOTE-181, second-line pembrolizumab reduced risk of death by 31% relative to chemotherapy among patients whose esophageal...
Conference Coverage
Age may dictate benefit of andecaliximab in gastric cancer
SAN FRANCISCO – Older adults appeared to derive both progression-free and overall survival benefit in the GAMMA-1 trial, which tested addition of...
Conference Coverage
COLOPEC: Adjuvant HIPEC for high-risk colon cancer disappoints
SAN FRANCISCO – Adding adjuvant oxaliplatin HIPEC to routine adjuvant systemic chemotherapy did not improve survival without peritoneal recurrence...
Video
Four-drug combo shows durable responses in relapsed/refractory lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
Conference Coverage
Long-term mogamulizumab appears safe, effective in CTCL
LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.
Conference Coverage
Investigational gene therapy shows promise in hemophilia A
SAN DIEGO – Investigational SPK-8011 gene transfer therapy results in dose-dependent FVIII expression in patients with severe hemophilia A.
Conference Coverage
Next-generation anti-BCMA CAR T shows promise for RRMM
SAN DIEGO – CAR T cells have been detectable up to 9 months after infusion.
Conference Coverage
Chidamide may be more effective in PTCL than previously thought
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
Conference Coverage
Epigenetics is a hot topic at TCLF 2019
LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination...